Warren, others urge government to allow generics to Novo's blockbuster GLP-1s ahead of CEO hearing
Fierce Pharma
SEPTEMBER 23, 2024
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are pressing the government to use its “march-in” rights and allow generic versions | In a letter to HHS secretary Xavier Becerra, several lawmakers urged the government to allow generic licenses for Novo's GLP-1 medicines Ozempic (..)
Let's personalize your content